<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660101</url>
  </required_header>
  <id_info>
    <org_study_id>A/100/0501</org_study_id>
    <nct_id>NCT00660101</nct_id>
  </id_info>
  <brief_title>Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer</brief_title>
  <official_title>OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVAX Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVAX Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if a vaccine made from the patient's own tumor tissue can stimulate an immune&#xD;
      response against the patient's tumor cells. To determine the safety of the vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study the toxicity, safety and DTH response of DNP-modified autologous ovarian tumor cell&#xD;
      vaccine and the DTH response to unmodified ovarian tumor cells in patients with relapsed&#xD;
      ovarian cancer:&#xD;
&#xD;
        -  To determine the tolerability and toxicity of the treatment regimen&#xD;
&#xD;
        -  To determine whether O-Vax induces a DTH response to autologous, DNP-modified ovarian&#xD;
           cancer cells&#xD;
&#xD;
        -  To determine whether O-Vax induces a DTH response to autologous, unmodified ovarian&#xD;
           cancer cells&#xD;
&#xD;
      Study Population: Patients with recurrent epithelial ovarian cancer whose therapeutic tumor&#xD;
      surgery provides a mass which yields adequate tumor cells for vaccine preparation and&#xD;
      delayed-type hypersensitivity (DTH) testing&#xD;
&#xD;
      Study Design: A Phase I/IIa double-blind, three-dose, multi-center study&#xD;
&#xD;
      Investigational Product: O-Vax: DNP-modified autologous ovarian tumor cell vaccine&#xD;
&#xD;
      Dosage Form: Cell suspension&#xD;
&#xD;
      Route of Administration: Intradermal&#xD;
&#xD;
      Dosage and Treatment Schedule: Prior to enrollment in the study, one dose of 5 x 106 modified&#xD;
      and one dose of 5 x 106 unmodified autologous ovarian cancer cells will be administered, to&#xD;
      establish a negative DTH response at baseline. Three dosing regimens will be used: 5 x 105,&#xD;
      2.5 x 106, or 5 x 106 DNP-modified autologous ovarian tumor cells. An initial dose of&#xD;
      DNP-modified autologous ovarian tumor cells* followed by cyclophosphamide then weekly doses&#xD;
      of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin&#xD;
      (BCG) for 6 weeks, and completed with one dose of DNP-modified autologous ovarian tumor cells&#xD;
      mixed with BCG as a 6 month booster if adequate cells&#xD;
&#xD;
        -  count determined prior to aliquoting for cryopreservation&#xD;
&#xD;
      Endpoints: Treatment-emergent and related adverse events, serious adverse events, and Grade 3&#xD;
      and 4 laboratory abnormalities&#xD;
&#xD;
      Other Parameters:&#xD;
&#xD;
        -  Delayed-type hypersensitivity skin reactions for assessing the induction of immune&#xD;
           responses to DNP-modified and unmodified autologous ovarian tumor cells&#xD;
&#xD;
        -  CA-125 levels&#xD;
&#xD;
        -  Survival&#xD;
&#xD;
        -  Exploratory analysis incorporating in vitro analysis of lymphocytes separated from&#xD;
           patient blood samples&#xD;
&#xD;
      Duration of Treatment: Up to 6 months&#xD;
&#xD;
      Duration of Subject Participation in Study: Three months from the patient's last vaccine&#xD;
&#xD;
      Duration of Follow-up: Survival information will be collected via phone or visit on a&#xD;
      quarterly basis for each patient beginning 30 days after the last scheduled visit&#xD;
&#xD;
      Number of Subjects Required to Meet Protocol Objectives: 42 evaluable subjects&#xD;
&#xD;
      Number of Study Centers: 4-5&#xD;
&#xD;
      Number of Individual Blood Draws: 13 draws over nine months&#xD;
&#xD;
      Volume of Blood Drawn: 11 Draws of 30 mL/draw (total 360 mL) and two draws of 50mL in&#xD;
      heparinized tubes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cell-mediated immunity to autologous tumor cells</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Adenocarcinoma of the Ovary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine</intervention_name>
    <description>OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>OVax</other_name>
    <other_name>O-Vax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Screening Phase&#xD;
&#xD;
          -  Stage III or IV adenocarcinoma of ovary&#xD;
&#xD;
          -  Candidate for surgery to excise the tumor&#xD;
&#xD;
          -  Signed informed consent for tumor acquisition&#xD;
&#xD;
        Treatment Phase&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Standard surgical debulking to maximum extent possible&#xD;
&#xD;
          -  Adequate amount of tumor tissue obtained from surgical debulking to prepare a series&#xD;
             of vaccines and skin test materials.&#xD;
&#xD;
          -  Administration of intraperitoneal chemotherapy following surgical debulking&#xD;
             Intraperitoneal drug to consist of a taxane (paclitaxel or docetaxel) Dose of taxane:&#xD;
             paclitaxel=60-75 mg/m2 / weekly x 4 or docetaxel = 25 mg/m2 - weekly x 4&#xD;
&#xD;
          -  Vaccines and DTH materials pass lot release&#xD;
&#xD;
          -  Minimum of 2 weeks and maximum of 6 weeks following last dose of intraperitoneal&#xD;
             chemotherapy&#xD;
&#xD;
          -  Immunocompetent, as determined by anergy panel performed 1 week after last dose of&#xD;
             intraperitoneal chemotherapy (baseline PPD+ patients allowed)&#xD;
&#xD;
          -  Expected survival of at least 6 months&#xD;
&#xD;
          -  Karnofsky performance status ³ 80&#xD;
&#xD;
          -  Signed informed consent for protocol participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Hemoglobin &lt; 10.0 g/dL&#xD;
&#xD;
          -  WBC &lt; 3,000 /mm3&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm3&#xD;
&#xD;
          -  Major field radiotherapy within 6 months prior to participation in the study&#xD;
&#xD;
          -  Brain metastases, unless successfully treated at least 6 months prior to entry&#xD;
&#xD;
          -  Prior immunotherapy (interferons, tumor necrosis factor, other cytokines [e.g.,&#xD;
             interleukins], biological response modifiers, or monoclonal antibodies) within 4 weeks&#xD;
             prior to participation in the study&#xD;
&#xD;
          -  Prior splenectomy&#xD;
&#xD;
          -  Concurrent use of systemic steroids (Note: Topical steroid therapies [applied to the&#xD;
             skin] are not contraindicated for participation in the study, provided these are not&#xD;
             applied to either arm. Inhaled aerosol steroids are not contraindicated for&#xD;
             participation in the study.)&#xD;
&#xD;
          -  Concurrent use of immunosuppressive drugs&#xD;
&#xD;
          -  Concurrent use of antitubercular drugs (isoniazid, rifampin, streptomycin)&#xD;
&#xD;
          -  Other malignancy within 5 years except curatively treated non-melanomatous skin cancer&#xD;
             and curatively treated carcinoma in situ of the uterine cervix&#xD;
&#xD;
          -  Concurrent autoimmune diseases, e.g., systemic lupus erythematosus, multiple sclerosis&#xD;
             or ankylosing spondylitis&#xD;
&#xD;
          -  Concurrent medical condition that would preclude compliance or immunologic response to&#xD;
             study treatment&#xD;
&#xD;
          -  Concurrent serious infection or other serious medical condition&#xD;
&#xD;
          -  Receipt of any investigational medication within 4 weeks prior to participation in the&#xD;
             study&#xD;
&#xD;
          -  Known gentamicin sensitivity&#xD;
&#xD;
          -  Anergic, defined by the inability to make a DTH to at least one of the following:&#xD;
             candida, mumps, tetanus, trichophyton (based upon availability), or PPD&#xD;
&#xD;
          -  Vaccine lot release failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry E Schea</last_name>
    <role>Study Director</role>
    <affiliation>AVAX Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America (CTCA-Midwestern)</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America (CTCA-Southwestern)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America (ERMC)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.avax-tech.com</url>
    <description>AVAX Technologies</description>
  </link>
  <link>
    <url>http://www.cancercenter.com</url>
    <description>Cancer Treatment Centers of America</description>
  </link>
  <reference>
    <citation>Dunton CJ, Carlson JA, King SA, Bloome E, Neufeld J, Berd D. Immunological and clinical effects of autologous hapten-modified vaccine in patients with advanced ovarian carcinoma., 19: Abstract 1828 ed 2000. p. 466a.</citation>
  </reference>
  <reference>
    <citation>Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1;22(3):403-15. Epub 2003 Dec 22.</citation>
    <PMID>14691123</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

